Item 8.01. Other Events.



On September 17, 2021, BeiGene, Ltd. ("BeiGene") announced that the Committee
for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
(EMA) has adopted a positive opinion, recommending approval of BRUKINSA
(zanubrutinib) for the treatment of adult patients with Waldenström's
macroglobulinemia (WM) who have received at least one prior therapy or
first-line treatment for patients unsuitable for chemo-immunotherapy. The full
text of this press release is filed as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated herein by reference.

On September 20, 2021, BeiGene announced its inclusion in several FTSE Russell
indices, including: the FTSE Global Equity Index Large Cap; the FTSE All-World
(LM); the FTSE All-Cap (LMS); and the FTSE Total-Cap (LMSµ). In addition,
BeiGene has also been included in the FTSE Developed ESG Low Carbon Select
Index, and the FTSE Asia ex Japan ESG Low Carbon Select Index, reflecting the
company's commitment to sustainability. The company's inclusion on the FTSE
indices became effective on Friday, September 17, 2021, after U.S. market close.
The full text of this press release is filed as Exhibit 99.2 to this Current
Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "BeiGene Receives Positive

CHMP Opinion for BRUKINSA®


                          (Zanubrutinib) for the Treatment of Adults with

Waldenström's Macroglobulinemia",


                          issued by BeiGene, Ltd. on September 17, 2021.

       99.2               Press Release titled "BeiGene Announces Inclusion

in FTSE Russell Indices", issued


                          by BeiGene, Ltd. on September 20, 2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL


--------------------------------------------------------------------------------


                                 Exhibit Index

   Exhibit No.            Description

       99.1                 Press Release titled "    BeiGene Receives

Positive CHMP Opinion for


                          BRUKINSA    ®     (Zanubrutinib) for the

Treatment of Adults with Waldenström's


                          Macroglobulinemia    ", issued by BeiGene, Ltd.

on September 17, 2021.



       99.2                 Press Release titled "    BeiGene Announces

Inclusion in FTSE Russell


                          Indices    ", issued by BeiGene, Ltd. on

September 2 0 , 2021.


       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses